Belgium-based brain imaging company icometrix achieves a significant milestone as it obtains a CPT III code from the American Medical Association. This achievement enables reimbursement for icometrix’s FDA-approved and CE-marked brain MRI quantification software, highlighting its value in the medical field.
The acquisition of a CPT III code from the American Medical Association marks a key milestone for icometrix, a brain imaging business with AI technology based in Belgium. Their FDA-approved and CE-marked brain MRI quantification software is reimbursable thanks to this code.
The software developed by icometrix is designed to analyze medical images and assist healthcare providers in diagnosing and monitoring patients with neurological conditions. By providing quantitative metrics for cerebral MRI scans, the AI-supported software aids clinicians in evaluating treatment responses and tracking the progression of diseases such as Alzheimer’s disease, dementia, multiple sclerosis, epilepsy, stroke, and Parkinson’s disease.
With the inclusion of the CPT code, qualified healthcare professionals can now report their utilization of icometrix’s brain imaging AI software as a practice expense. This development further supports the adoption and integration of innovative technologies in the field of healthcare.
In 2019, icometrix secured $18 million in funding to expand the capabilities of its brain software. The company received FDA clearance for its icobrain-ctp offering in February 2020, solidifying its commitment to providing advanced solutions in the medical imaging domain.
Recently, icometrix received a grant from the Michael J. Fox Foundation to collaborate with a professor from Stanford Medicine in researching brain MRI biomarkers for Parkinson’s disease. This partnership exemplifies Icometrix’s dedication to pushing the boundaries of medical imaging and neurological research.
Moreover, icometrix was awarded a £1,417,658 ($1,798,944) grant from the National Institute for Health and Care Research in March to expedite research in the field of multiple sclerosis imaging.
The utilization of AI software to aid in the diagnosis of brain disorders is not exclusive to icometrix. South Korean health tech company Neurophet also made strides in this area by obtaining certification from Singapore’s Health Sciences Authority for its AI-enabled degenerative brain disease diagnosis assistant software in April.
These advancements in AI-enabled brain imaging technology demonstrate the ongoing trend of integrating innovative solutions into medical practice, ultimately benefiting patients and healthcare providers alike.
